» Articles » PMID: 35478470

Biomarker Based Biosensors: An Opportunity for Diagnosis of COVID-19

Overview
Journal Rev Med Virol
Publisher Wiley
Specialty Microbiology
Date 2022 Apr 28
PMID 35478470
Authors
Affiliations
Soon will be listed here.
Abstract

Early diagnosis and treatment of diseases are crucial research areas of human health. For early diagnosis, one method that has proven efficient is the detection of biomarkers which can provide real-time and accurate biological information. Most biomarker detection is currently carried out at localised dedicated laboratories using large and automated analysers, increasing waiting time and costs. Smaller, faster, and cheaper devices could potentially replace these time-consuming laboratory analyses and make analytical results available as point-of-care diagnostics. Innovative biosensor-based strategies could allow biomarkers to be tested reliably in a decentralised setting. Early diagnosis of COVID-19 patients has a key role in order to use quarantine and treatment strategies in a timely manner. Raised levels of several biomarkers in COVID-19 patients are associated with respiratory infections or dysfunction of various organs. Through clinical studies of COVID-19 patient biomarkers such as ferritin, Interleukins, albumin and …are found to reveals significant differences in their excretion ranges from healthy patients and patients with SARS-CoV-2, in addition to the development of biomarkers based biosensor such as stated biomarkers can be used and to investigate more specific biomarkers further proteomic analysis can be performed. This review presents several biomarker alterations in COVID-19 patients such as salivary, circulatory, coagulation, cardiovascular, renal, liver, C-reactive protein (CRP), immunological and inflammatory biomarkers. Also, biomarker sensors based on electrochemical, optical, and lateral flow characteristics which have potential applications for SARS-COV-2 in the recent COVID-19 pandemic, will be discussed.

Citing Articles

Therapeutic potential and possible mechanisms of ginseng for depression associated with COVID-19.

Zhao F, Zhang K, Chen H, Zhang T, Zhao J, Lv Q Inflammopharmacology. 2023; 32(1):229-247.

PMID: 38012459 PMC: 10907431. DOI: 10.1007/s10787-023-01380-0.


Advances in Biosensing Technologies for Diagnosis of COVID-19.

Alsalameh S, Alnajjar K, Makhzoum T, Al Eman N, Shakir I, Mir T Biosensors (Basel). 2022; 12(10).

PMID: 36291035 PMC: 9599206. DOI: 10.3390/bios12100898.


Biomarker based biosensors: An opportunity for diagnosis of COVID-19.

Khaksarinejad R, Arabpour Z, Rezakhani L, Parvizpour F, Rasmi Y Rev Med Virol. 2022; 32(5):e2356.

PMID: 35478470 PMC: 9111147. DOI: 10.1002/rmv.2356.

References
1.
Hajian R, Balderston S, Tran T, deBoer T, Etienne J, Sandhu M . Detection of unamplified target genes via CRISPR-Cas9 immobilized on a graphene field-effect transistor. Nat Biomed Eng. 2019; 3(6):427-437. PMC: 6556128. DOI: 10.1038/s41551-019-0371-x. View

2.
Deshpande P, Ramachandran C, Sefat F, Mariappan I, Johnson C, Mckean R . Simplifying corneal surface regeneration using a biodegradable synthetic membrane and limbal tissue explants. Biomaterials. 2013; 34(21):5088-106. DOI: 10.1016/j.biomaterials.2013.03.064. View

3.
Xu J, Li Y, Gan F, Du Y, Yao Y . Salivary Glands: Potential Reservoirs for COVID-19 Asymptomatic Infection. J Dent Res. 2020; 99(8):989. DOI: 10.1177/0022034520918518. View

4.
Joyner M, Bruno K, Klassen S, Kunze K, Johnson P, Lesser E . Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. Mayo Clin Proc. 2020; 95(9):1888-1897. PMC: 7368917. DOI: 10.1016/j.mayocp.2020.06.028. View

5.
Inciardi R, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D . Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020; 5(7):819-824. PMC: 7364333. DOI: 10.1001/jamacardio.2020.1096. View